Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Knowing when to sell index funds in a recession helps protect capital and rebalance for future growth. This intro offers timing considerations.
15,106 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
A Tuesday uptick in Edgewise Therapeutics stock topped the market, driven by an upbeat price target from a major bank...
Playnance has kicked off GCOIN trading on MEXC, signaling a key expansion of its Web3 entertainment network. Early me...
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
As tax season kicks off, the IRS unveils its 2026 Dirty Dozen and warns taxpayers about increasingly sophisticated sc...
The Midwest multifamily investment sector heating is gaining momentum as rates stabilize and rental demand strengthen...
Palantir stock sits at a valuation well above the market average. This piece breaks down what that 2,500% gap means, ...
Public life tests more than reputations—it tests money boundaries too. This article uses the phrase 'mayor kept calli...
MSFO continues to pay weekly distributions despite a sharp stock slide in Microsoft. As MSFT falls, MSFO investors we...
In March 2026, traders are eyeing the best stocks under $5 as market volatility creates opportunities for disciplined...
Interloom just raised $16.5 million to convert tacit knowledge into AI-driven workflow tools. The Munich startup says...
Japan sees renewed toilet paper stockpiling as global oil-market jitters ripple through households. Officials urge ca...